DTIC for the Treatment of Canine Melanoma

Description

DTIC is considered the gold standard of chemotherapy treatment for melanoma in people. The goal of this study is to determine the efficacy of DTIC in treating dogs with this highly malignant cancer.

Inclusion Criteria

Dogs must have measurable tumor either at the primary site or metastasis and must be in good clinical condition.

Exclusion Criteria

Dog whose life expectancy is less than 3 months or whole have significant liver disease are ineligible from participating in this clinical trial.

Client Benefits

The owner is financially responsible for all tests that determine if the patient qualifies for the study. These tests may include initial specialty examination, chest x-rays, blood and urine tests.

This study covers the cost of two cycles of DTIC chemotherapy including re-check examination fee and cost of pre-treatment CBC/plt count.

Contact Information

Kelly Reed, Oncology Liaison
Phone: (508) 887-4682